Testosterone Cypionate
Testosterone esterified with cypionate, a long-acting oil-based injectable. Reference entry for the calculators, not tracked for price.
Reference compound, not sold here. Profile for research context only.
Overview
Testosterone cypionate is the 17β-cyclopentylpropionate ester of testosterone: the parent hormone with an eight-carbon, ring-containing fatty-acid chain on its 17β-hydroxyl, dissolved in cottonseed oil for slow release from an intramuscular depot. This is a reference entry, not a product the index tracks — no cypionate listings or prices appear here. It exists because the parent page's half-life, interval and formulation questions cannot be answered without naming the ester. Two US products are FDA-approved: Depo-Testosterone (Pharmacia & Upjohn, a Pfizer company) and Azmiro (Azurity), both for replacement in males with primary or hypogonadotropic hypogonadism. It is a Schedule III controlled substance and, as a testosterone ester, prohibited at all times under WADA class S1. Nothing here is dosing or treatment advice.
Chemistry#
C27H40O3, 412.6 g/mol (the Depo-Testosterone label prints 412.61), CAS 58-20-8, PubChem CID 441404. The ester is 3-cyclopentylpropionate — eight carbons including the cyclopentyl ring — so by molecular weight roughly 70% of the mass is testosterone (288.4/412.6, arithmetic from the two sourced weights). The steroid core is unchanged; the chain adds no activity of its own and only sets how fast testosterone leaves the oil.
Formulation#
Depo-Testosterone is supplied at 100 mg/mL and 200 mg/mL (the 50 mg/mL strength was discontinued) in cottonseed oil — 736 mg/mL or 560 mg/mL respectively — with benzyl benzoate (0.1 or 0.2 mL per mL) and 9.45 mg/mL benzyl alcohol as preservative; deep gluteal intramuscular injection only, never intravenous. Its application is ANDA 085635, originally approved 1979-07-25. Azmiro is a 200 mg/mL single-dose vial and prefilled syringe in 542 mg/mL cottonseed oil with benzyl benzoate and 20 mg/mL benzyl alcohol, label revised 7/2025. Both labels give the same replacement interval: 50–400 mg every two to four weeks. No subcutaneous cypionate product is approved; SC use is off-label (Spratt 2017, McFarland 2017).
History#
A 1954 Metabolism paper already compared the anabolic effects of testosterone cyclopentylpropionate with testosterone propionate in humans, placing clinical use in the early 1950s. Depo-Testosterone is an Upjohn brand; secondary sources give 1951 as its US introduction, but no primary document for that year was verified, so the dated fact used here is the ANDA's 1979 approval. Azmiro, the prefilled 200 mg/mL presentation, is the newest cypionate product; trade press places its US availability in late 2024 to early 2025, and its FDA application number was not found in Drugs@FDA during this pass.
How it works
The ester is not the active species. What reaches the androgen receptor is testosterone, released from the depot, so mechanism — direct androgen-receptor agonism, reduction to dihydrotestosterone, feedback suppression of pituitary LH and of spermatogenesis — is the parent's and is described on the testosterone profile.
Pharmacokinetics#
The label states that the half-life of testosterone cypionate injected intramuscularly is approximately eight days; the Azmiro label repeats the figure. This is an apparent, absorption-limited half-life: free testosterone clears in minutes (the parent profile's 27-minute slow phase), so after a depot injection serum testosterone declines at the rate the oil releases ester — "flip-flop" kinetics — and the eight days describe the cottonseed-oil depot, not the molecule. Neither label gives a range, a study population, a subcutaneous value, or says which compartment was fitted, which is why the numeric entry carries no range. Nankin's 1987 study of 11 hypogonadal men given 200 mg IM supplies the shape of the curve: serum testosterone peaked on days 2–5 and had declined to basal levels by days 13–14 — the swing that two-week intervals are built around.
Evidence
Every study below used testosterone cypionate specifically. Pharmacokinetics: Nankin 1987 (11 hypogonadal men, 200 mg IM biweekly) documented the day 2–5 peak and day 13–14 return to baseline. Ester comparison: Schulte-Beerbühl and Nieschlag (1980) measured serum testosterone, DHT, LH and FSH after injection of enanthate or cypionate head-to-head. Subcutaneous administration: Spratt 2017 reported a retrospective cohort of 63 transgender men in which all 22 who switched from IM to SC preferred it; McFarland 2017 found serum testosterone stable between injections on weekly SC cypionate. Masculinising hormone therapy: the 2017 Endocrine Society guideline lists parenteral testosterone esters (cypionate or enanthate) among its regimens for transgender men. Historical: the 1954 anabolic comparison with propionate. The large cardiovascular outcome trial often quoted for testosterone, TRAVERSE (2023), used transdermal gel, not cypionate, so its findings transfer only as class evidence.
Anecdotal reports community-reported
What people describe in forums, blogs and uncontrolled clinic write-ups — experiential and unverified, not clinical evidence and not medical advice.
- Cypionate vs enanthate: no practical differencecommonly reported
The dominant verdict is that cypionate and enanthate are interchangeable at the same dose, with users switching mid-cycle or rotating between the two for daily sub-Q shots and noticing nothing. Those with a preference usually say cypionate is smoother (less post-injection pain or acne than their enanthate) or simply more available in North America; a few report lower blood levels on cypionate.
- Peaks, troughs and injection frequencycommonly reported
Users report troughs anywhere from under 400 to over 1,200 ng/dL on the same 200 mg/week, and many say splitting into every-other-day or three-times-weekly shots evened out mood, estradiol and hematocrit. Others feel fine on one or two shots a week, and injection site (lean delt vs fattier glute, deep vs shallow) is often blamed for inconsistent labs.
- Worse libido on 200 mg once weeklya sizeable minority
Some users on a once-weekly 200 mg clinic protocol describe acne, water retention, headaches and worse rather than better libido, with total testosterone only mid-range at day eight. The usual replies are to cut toward 100 mg, split into two or more shots or move to sub-Q; others insist once weekly works fine for them and that libido is best for them at lower doses.
- Results on replacement dosescommonly reported
Users on 150 mg/week split over three days report better drive and mood after one to two months and visible body change by four or five, often alongside diet changes, less drinking or a GLP-1. Some reply that a replacement dose alone would not produce the pictured change and credit the other drug; sleep is often said not to improve.
- First-injection expectationscommonly reported
Users say a single injection produces nothing noticeable and that effects build over three to six weeks, with the clearest changes at three months to a year. A 200 mg weekly start is widely called high, with 120–150 mg suggested as an easier ride, and several warn of a hormonal rollercoaster with high estradiol until the dose is dialled in.
Safety
Class risks — erythrocytosis, androgenic skin effects, gynecomastia, fluid retention, suppressed spermatogenesis, mood change, venous thromboembolism, and the abuse syndrome in every label — are the parent hormone's and are set out on the testosterone profile. Specific to this ester and its products: the current Depo-Testosterone label warns that testosterone can increase blood pressure and so raise cardiovascular risk over time, but, unlike Aveed, cypionate carries no boxed warning and no REMS. The vehicle matters for hypersensitivity — cottonseed oil, benzyl benzoate and a benzyl alcohol preservative (20 mg/mL in Azmiro). The label's abuse-and-dependence section notes that testosterone has been subject to abuse, typically at doses higher than recommended. The Azmiro label states that safety and efficacy have not been established for age-related hypogonadism. Prescription-only Schedule III; the safety score of 3 mirrors the parent's — a well-mapped but materially risky hormone — and would be lower for unlabeled or underground products.
Reported side effects
Reported in published literature and user reports. Not a complete list, and not medical advice.
- Class effects of testosterone — erythrocytosis, acne, gynecomastia, fluid retention, suppressed spermatogenesis, mood changes, venous thromboembolism (see the testosterone profile)
- Blood-pressure increases, warned on the current Depo-Testosterone label as a cardiovascular risk over time
- Injection-site pain and inflammation from the oil depot (deep gluteal IM only)
- Hypersensitivity to the vehicle — cottonseed oil, benzyl benzoate, benzyl alcohol preservative
- Abuse and dependence (label section) at doses higher than recommended
If severe or unexpected symptoms occur, contact a qualified medical professional. Peptides·Index does not provide medical advice.
Cautions discuss with a clinician
- Known or suspected carcinoma of the prostate, or breast carcinoma in men (Depo-Testosterone label)
- Women who are pregnant — virilisation of the female fetus; cypionate is not indicated in women (label)
- Serious cardiac, hepatic or renal disease — fluid retention and edema risk (label)
- Known hypersensitivity to the drug or to cottonseed oil, benzyl benzoate or benzyl alcohol (label)
- Oral anticoagulants (warfarin)Androgens increase sensitivity; the anticoagulant dose may need reduction (Depo-Testosterone label)
- Insulin and other antidiabetic drugsAndrogens may lower blood glucose and reduce insulin requirements (label)
- OxyphenbutazoneSerum oxyphenbutazone levels may rise with concurrent androgens (label)
- Thyroid function testsAndrogens lower thyroxine-binding globulin, reducing total T4 while free hormone stays normal (label)
Timeline commonly reported
- Days 2–5
Serum testosterone peaked between days 2 and 5 after a single 200 mg IM dose in 11 hypogonadal men (Nankin 1987).
- Days 13–14
In the same study serum testosterone had declined to basal levels by days 13 to 14 — the peak-to-trough swing behind two-week dosing intervals and the label's ~8-day half-life.
- Weeks to months
Downstream effects (libido, mood, body composition, erythropoiesis, bone) follow the testosterone timeline, not the ester's — see the testosterone profile.
FAQ
Is testosterone cypionate a peptide?
No. It is a steroid ester — testosterone (C19H28O2) with a 3-cyclopentylpropionate chain on the 17β-hydroxyl, giving C27H40O3 and 412.6 g/mol. It is a reference entry here so the parent testosterone page can compare esters; the index does not track cypionate products or prices.
How long does testosterone cypionate last?
The Depo-Testosterone and Azmiro labels both state the half-life after intramuscular injection is approximately eight days. That is an apparent, absorption-limited figure — serum testosterone falls at the rate the oil depot releases ester, not the minutes it takes the body to clear testosterone itself. In Nankin's 1987 study levels peaked at days 2–5 and were back to baseline by days 13–14 after 200 mg.
Can cypionate be injected subcutaneously?
No approved SC cypionate product exists; the labels specify deep gluteal intramuscular injection. SC use has been studied off-label — Spratt 2017 (63 transgender men, all 22 who switched preferred SC) and McFarland 2017 (stable between-injection levels with weekly SC cypionate). The only FDA-approved subcutaneous testosterone ester is enanthate (Xyosted).
What oil is testosterone cypionate in?
Cottonseed oil. Depo-Testosterone contains 736 mg/mL (100 mg/mL strength) or 560 mg/mL (200 mg/mL strength) of cottonseed oil with benzyl benzoate and 9.45 mg/mL benzyl alcohol as preservative; Azmiro uses 542 mg/mL cottonseed oil, benzyl benzoate and 20 mg/mL benzyl alcohol. Enanthate products use sesame oil and Aveed uses castor oil, which matters for oil allergies.
Is cypionate different from enanthate?
Chemically yes — an 8-carbon ring-containing ester versus a straight 7-carbon chain, 412.6 vs 400.6 g/mol — and the US labels differ: cypionate's states an ~8-day half-life, enanthate's states none. A 1980 head-to-head study measured serum testosterone, DHT, LH and FSH after injection of either ester (Schulte-Beerbühl and Nieschlag). Both are labeled at 50–400 mg every 2–4 weeks.
Sources
Starting references for the library summary. These are not dosing instructions or medical advice.
For research-use educational context only. Not medical advice and not a recommendation to use any compound. Consult a qualified healthcare professional before any health decision.